De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Bluestar Adisseo Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Bluestar Adisseo heeft een totaal eigen vermogen van CN¥15.2B en een totale schuld van CN¥1.2B, wat de schuld-eigenvermogensverhouding op 8.1% brengt. De totale activa en totale passiva bedragen respectievelijk CN¥21.4B en CN¥6.2B. De EBIT Bluestar Adisseo is CN¥1.1B waardoor de rentedekking 14.4 is. Het heeft contanten en kortetermijnbeleggingen van CN¥1.0B.

Belangrijke informatie

8.1%

Verhouding schuld/eigen vermogen

CN¥1.23b

Schuld

Rente dekkingsratio	14.4x
Contant	CN¥1.02b
Aandelen	CN¥15.19b
Totaal verplichtingen	CN¥6.23b
Totaal activa	CN¥21.42b

Recente financiële gezondheidsupdates

Is Bluestar Adisseo (SHSE:600299) A Risky Investment?

Mar 27

Recent updates

Bluestar Adisseo's (SHSE:600299) Returns On Capital Not Reflecting Well On The Business

Apr 25

There May Be Some Bright Spots In Bluestar Adisseo's (SHSE:600299) Earnings

Apr 04

Is Bluestar Adisseo (SHSE:600299) A Risky Investment?

Mar 27

Optimistic Investors Push Bluestar Adisseo Company (SHSE:600299) Shares Up 25% But Growth Is Lacking

Mar 06

Is There An Opportunity With Bluestar Adisseo Company's (SHSE:600299) 32% Undervaluation?

Feb 28

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( CN¥5.8B ) 600299 } overtreffen de korte termijn passiva ( CN¥3.5B ).

Langlopende schulden: De kortetermijnactiva 600299 ( CN¥5.8B ) overtreffen de langetermijnschulden ( CN¥2.8B ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 1.4% ) 600299 wordt als voldoende beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van 600299 is de afgelopen 5 jaar gestegen van 0.2% naar 8.1%.

Schuldendekking: De schuld van 600299 wordt goed gedekt door de operationele kasstroom ( 229% ).

Rentedekking: De rentebetalingen op de schuld van 600299 worden goed gedekt door EBIT ( 14.4 x dekking).

Bluestar Adisseo Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Is Bluestar Adisseo (SHSE:600299) A Risky Investment?

Recent updates

Bluestar Adisseo Company to Report Q3, 2024 Results on Oct 30, 2024

Investor sentiment improves as stock rises 16%

Bluestar Adisseo (SHSE:600299) Is Finding It Tricky To Allocate Its Capital

Second quarter 2024 earnings: EPS in line with expectations, revenues disappoint

Getting In Cheap On Bluestar Adisseo Company (SHSE:600299) Is Unlikely

Price target increased by 12% to CN¥11.23

Bluestar Adisseo Company to Report First Half, 2024 Results on Aug 30, 2024

Are Investors Undervaluing Bluestar Adisseo Company (SHSE:600299) By 32%?

Bluestar Adisseo Company, Annual General Meeting, Jun 26, 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Bluestar Adisseo Company announced that it expects to receive CNY 3 billion in funding

Bluestar Adisseo's (SHSE:600299) Returns On Capital Not Reflecting Well On The Business

There May Be Some Bright Spots In Bluestar Adisseo's (SHSE:600299) Earnings

Full year 2023 earnings: EPS and revenues miss analyst expectations

Bluestar Adisseo Company to Report Q1, 2024 Results on Apr 26, 2024

Is Bluestar Adisseo (SHSE:600299) A Risky Investment?

Consensus EPS estimates increase by 21%

Optimistic Investors Push Bluestar Adisseo Company (SHSE:600299) Shares Up 25% But Growth Is Lacking

Is There An Opportunity With Bluestar Adisseo Company's (SHSE:600299) 32% Undervaluation?

Bluestar Adisseo Company to Report Fiscal Year 2023 Results on Mar 29, 2024

Consensus EPS estimates increase by 10%, revenue downgraded

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Earnings quality

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Bluestar Adisseo Company to Report First Half, 2023 Results on Aug 05, 2023

Consensus revenue estimates decrease by 17%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 7.6% to CN¥11.84

Less than half of directors are independent

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improved over the past week

Price target decreased to CN¥12.76

Consensus EPS estimates fall by 22%

Second quarter 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.16 in 2Q 2021)

Price target decreased to CN¥13.40

Bluestar Adisseo Company, Annual General Meeting, May 16, 2022

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Less than half of directors are independent

Bluestar Adisseo Company, Annual General Meeting, Apr 29, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.14 in 3Q 2020)

Less than half of directors are independent

Price target decreased to CN¥15.11

Second quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.16 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.11 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.50 (vs CN¥0.37 in FY 2019)

New 90-day high: CN¥14.80

Investor sentiment improved over the past week

New 90-day low: CN¥11.07

New 90-day low: CN¥11.88

Third quarter earnings released

Third-quarter earnings released: Revenue misses expectations

Bluestar Adisseo Company to Report Q3, 2020 Results on Oct 30, 2020

New 90-day low: CN¥12.50

Bluestar Adisseo Company (SHSE:600299) signed an agreement to acquire FraMelco B.V. from a family.

Bluestar Adisseo Company (SHSE:600299) completed the acquisition remaining 15% stake in Blue Star Adisseo Nutrition Group Co., Ltd. from China National BlueStar (Group) Co., Ltd.

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven